What Are the Benefits of Aldosterone Antagonists in Real-World HF Treatment?

In a study of registry data, these agents were associated with reductions in HF hospitalization but not mortality or cardiovascular readmission.

Despite trial evidence of the efficacy of aldosterone antagonists in patients with heart failure (HF), such agents are used in a minority of HF patients. These investigators analyzed data from the American Heart Association's Get With the Guidelines-Heart Failure registry and Medicare records to assess the effects of aldosterone antagonists on all-cause mortality, cardiovascular and HF readmissions, and hyperkalemia in patients aged ≥65 with HF and reduced ejection fractions (EFs).

Of 5887 patients who had not previously received aldosterone antagonist therapy, 18.2% received a prescription for an aldosterone antagonist at hospital discharge. Compared with nonrecipients, aldosterone antagonist recipients were younger, were more likely to rec…

Reviewing Author

Joel M. Gore, MD

Disclosures

Grant/Research SupportNIH–National Heart, Lung, and Blood Institute

Joel M. Gore, MD

Disclosures

Grant/Research SupportNIH–National Heart, Lung, and Blood Institute

What Are the Benefits of Aldosterone Antagonists in Real-World HF Treatment?

Topics

Reviewing Author